Tropic Biosciences Raises $105 Million Series C to Scale Gene-Edited Tropical Crop Production
核心洞察
Tropic Biosciences (搜索) secured an oversubscribed $105 million Series C financing round co-led by Forbion Bioeconomy Fund (搜索) and Corteva (搜索) to expand commercial production of gene-edited tropical crops.
The funding will accelerate development of banana varieties with natural resistance to devastating diseases including TR4 (搜索) and Black Sigatoka (搜索), while expanding rice portfolio development.
Capital will be used to scale large-scale plant production capabilities and strengthen global supply chains as demand for initial commercial products rapidly outpaces current supply capacity.
Tropic Biosciences (搜索) has successfully closed an oversubscribed $105 million Series C financing round to accelerate the commercial rollout of gene-edited tropical crops, addressing critical global food supply challenges. The round was co-led by Forbion through its Planetary Health Bioeconomy Fund and Corteva (搜索) through its Corteva Catalyst investment platform, with significant participation from Just Climate (搜索) and IQ Capital (搜索).
The tropical seeds company, which develops healthier, more robust, high-performing varieties of staple crops, attracted substantial investor interest with the round also supported by new investors ABN Amro (搜索) and Invest International (搜索). Existing investors Temasek (搜索), Five Seasons Ventures (搜索), Sucden Ventures, Genoa Ventures and Polaris Partners participated in the financing.
Scaling Production to Meet Growing Demand
With demand for its initial commercial products rapidly outpacing supply, Tropic will deploy the Series C capital to expand large-scale plant production capabilities and strengthen global supply chains. The funding will also support commercial partnerships across major export markets as the company scales its operations.
Disease-Resistant Crop Development Pipeline
The financing will accelerate Tropic's pipeline of banana varieties specifically developed for natural resistance to devastating diseases such as TR4 (搜索) and Black Sigatoka (搜索). These diseases pose significant threats to global banana production, making disease-resistant varieties critical for food security.
Beyond bananas, the funding will expand development across Tropic's rice portfolio and support entry into additional high-impact crops designed to address global food supply challenges. The company's gene-editing approach aims to create varieties that can withstand environmental pressures while maintaining nutritional value and yield performance.
Strategic Investment in Agricultural Innovation
The substantial investment reflects growing recognition of the need for innovative agricultural solutions to address food security challenges. The participation of both specialized bioeconomy funds and agricultural industry leaders demonstrates confidence in gene-editing technologies for crop improvement.
The oversubscribed nature of the financing round indicates strong investor appetite for agricultural biotechnology companies developing solutions for tropical crop production, particularly those addressing disease resistance and climate resilience in staple food crops.